Claudin 1 Antibody (LS-B2571)

貨號 Cat. No.
LS-B2571
規格 Size
125 µl
品牌 Brand
LSBio

Description

























































































Antibody Catalog ID: LS-B2571
Antibody Validation: This antibody replaces catalog number LS-C6143. It has been validated for use in the following assays: IHC-P.
Antibody Target: Claudin 1 (CLDN1)
Synonyms: CLDN1, claudin 1, CLD1, cldn1, ILVASC, SEMP1
Family: Claudin
Subfamily: not assigned-Claudin
Host: CLDN1 antibody was produced in Rabbit
Antigen Species: CLDN1 antibody was raised against Human
Clonality: Polyclonal
Antigen Type: Synthetic peptide
Immunogen: CLDN1 antibody was raised against a synthetic peptide derived from the C-terminus of human Claudin 1.
Antibody Specificity: Recognizes Claudin 1. Species cross-reactivity: Human, Monkey, Mouse, Canine, and Rat.
Antigen Modification: C-Terminus
Predicted Species Reactivity: Dog, Monkey, Mouse, Rat
Purification: Immunoaffinity Chromatography
Presentation: 10 mM PBS, pH 7.6, 0.2% BSA, 15 mM sodium azide, before the addition of glycerol to 40%
Recommended Storage: +4°C or -20°C, Avoid repeated freezing and thawing.
Antibody Usage Summary: Immunohistochemistry: LS-B2571 was validated for use in immunohistochemistry on a panel of 21 formalin-fixed, paraffin-embedded (FFPE) human tissues after heat induced antigen retrieval in pH 6.0 citrate buffer. After incubation with the primary antibody, slides were incubated with biotinylated secondary antibody LS-D1, followed by alkaline phosphatase-streptavidin and chromogen. The stained slides were evaluated by a pathologist to confirm staining specificity. The optimal working concentration for LS-B2571 was determined to be 5 ug/ml. Western Blot: 2-4 ug/ml for 2 hrs at RT. Positive control: T47D cells, Skin or Breast carcinoma.
Antibody Uses: Immunohistochemistry - Paraffin (IHC-P) (5 µg/ml), Western blot (WB), ELISA (Optimal dilution to be determined by the researcher)
Size: 125 µl
Concentration: 0.1 mg/ml

詢價 / 洽詢此產品

同品牌其他產品

回到產品列表

▲ LINE
諮詢